Regulatory Pathway for Biosimilars

The FDA evaluation of the evidence

The regulatory pathway for biosimilar medicines is a unique and thoughtful process. It is designed to help ensure the development and approval of high-quality biosimilar medicines. Approved biosimilar medicines have no clinically meaningful differences in terms of safety and efficacy from the relevant reference product, based on the totality of evidence from analytical, nonclinical, pharmacokinetic, and clinical studies. The totality of evidence is used by the FDA when evaluating new biosimilar products.

Robust standards for quality, efficacy, and safety

A closer look at
the totality of evidence

Robust analytical testing, including comparative structural and functional characterization, to establish high similarity of the biosimilar and the reference product
Nonclinical testing to evaluate the toxicity and safety profiles of the biosimilar
Comparative human pharmacokinetic and pharmacodynamic studies and clinical immunogenicity assessment
In certain cases, additional comparative clinical studies may be warranted to help ensure that there are no clinically meaningful differences between the products

The “totality of evidence” approach to determining biosimilarity

The aim of biosimilar drug development is to establish similarity to the reference product in terms of quality, safety, benefit/risk profile, and efficacy using a stepwise approach that includes analytical, nonclinical, and clinical comparability studies. In certain cases, additional comparative clinical studies may be warranted to help ensure that there are no clinically meaningful differences between the products.

Informational Videos for healthcare professionals

The pathway to

biosimilar approval

The FDA evaluation of the evidence

Robust standards for quality, efficacy, and safety

A closer look at
the totality of evidence

The “totality of evidence” approach to determining biosimilarity

You are now leaving Pfizer

The pathway to

biosimilar approval

The FDA evaluation of the evidence

Robust standards for quality, efficacy, and safety

A closer look at the totality of evidence

The “totality of evidence” approach to determining biosimilarity

You are now leaving Pfizer

A closer look at
the totality of evidence